# A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

> **NCT00394277** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1175 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00394277
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 1175 (ACTUAL)
- **Last updated:** 2010-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394277, "A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00394277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*